NeuroPace to Spotlight Epilepsy Tech at High-Stakes Investor Conference

MOUNTAIN VIEW, CA – March 05, 2026 – NeuroPace, Inc. is preparing for a pivotal presentation at the upcoming Leerink 2026 Global Healthcare Conference in Miami, a high-profile event that places the medical device company on the same stage as giants like Amgen and Eli Lilly. On March 11, the management team will step into the spotlight to detail the progress and potential of its innovative epilepsy treatment, the RNS System. For investors, clinicians, and patients, the presentation is more than a corporate update; it’s a window into the future of personalized neurological care and the business strategy driving it.

The company, traded on Nasdaq under the ticker NPCE, has announced that the 8:40 AM PT presentation will be webcast, signaling its intent to reach a broad audience of stakeholders. This moment provides NeuroPace a critical opportunity to articulate its value proposition, not just as a medical technology innovator but as a viable long-term investment in a competitive and rapidly evolving healthcare sector.

A Critical Platform in a Prestigious Arena

The Leerink Global Healthcare Conference is not just another industry gathering. It is a premier forum where the financial community convenes to assess the health and direction of the healthcare industry. For a specialized company like NeuroPace, securing a presentation slot is a significant achievement, offering direct access to discerning investors and influential analysts who can shape market perception and capital flow.

The conference agenda is a testament to its prestige, featuring presentations from many of the world's leading pharmaceutical, biotechnology, and medical device firms. In this environment, NeuroPace's story must be compelling and clear. Management will be tasked with translating complex clinical data and technological advantages into a narrative of sustainable growth and market leadership. The presentation, coupled with private investor meetings held during the conference, will be crucial for reinforcing confidence among existing shareholders and attracting new capital to fuel its mission.

"For a company in this stage of growth, these presentations are make-or-break moments," commented one healthcare industry analyst. "They need to demonstrate not only that the technology works, but that they have a sound strategy for market penetration, reimbursement, and scaling the business. The audience at Leerink is sophisticated; they'll be looking past the hype and scrutinizing the fundamentals."

The RNS System: A New Frontier in Epilepsy Treatment

At the heart of NeuroPace's story is its flagship product, the RNS System. Described as the first and only brain-responsive neurostimulation platform, it represents a paradigm shift in treating drug-resistant epilepsy, a condition affecting approximately one-third of all people with epilepsy. Unlike traditional treatments that may involve continuous stimulation or ablative surgery, the RNS System offers a personalized and dynamic approach.

The system consists of a small, implantable neurostimulator connected to tiny wires placed in the brain at the seizure source. It functions as a closed-loop platform, continuously monitoring brain activity to detect pre-seizure patterns. When it identifies activity that is likely to lead to a seizure, it delivers imperceptible electrical pulses to normalize the brainwaves and prevent the seizure before it starts. This real-time, responsive treatment is tailored to the individual's unique neural signature.

Perhaps its most revolutionary feature is the vast amount of long-term brain data it collects. This data provides unprecedented insights for clinicians, allowing them to fine-tune treatment and better understand a patient's specific condition. The press release notes the system "delivers personalized, real-time treatment at the seizure source," but its value extends beyond immediate intervention. It creates a powerful feedback loop between patient, device, and physician, driving a more informed and effective standard of care. This capability underpins the company's claim that its platform has the potential to expand into treating other brain disorders, an avenue investors will be keen to hear more about.

Navigating the Competitive Neuromodulation Market

While the RNS System is unique in its brain-responsive approach, NeuroPace operates within the broader, highly competitive neuromodulation market. This sector includes established, multi-billion dollar corporations with deep pockets and extensive market reach in neurological devices. To succeed, NeuroPace must effectively differentiate its technology and prove its clinical and economic value proposition.

The company faces the typical challenges of a disruptive medical device innovator: navigating complex regulatory pathways, securing favorable reimbursement from insurers, and educating a medical community that may be slow to adopt new technologies. Building a robust body of clinical evidence and demonstrating long-term patient benefits are paramount to overcoming these hurdles. The RNS System's ability to collect chronic electrocorticographic data is a significant advantage in this regard, providing a continuous stream of real-world evidence of its efficacy.

However, the market also presents immense opportunity. The trend toward personalized medicine is a powerful tailwind for NeuroPace's technology. As healthcare shifts from one-size-fits-all solutions to tailored interventions, platforms like the RNS System are positioned to lead the way. The unmet need in drug-resistant epilepsy remains vast, and the potential to apply its brain-responsive technology to other conditions like Parkinson's disease or Tourette syndrome represents a massive potential for expansion.

Investor Expectations and the Path Forward

When NeuroPace management takes the stage in Miami, they will be addressing an audience focused on the path to profitability and long-term growth. Investors will be listening intently for updates on key performance metrics, such as the number of RNS System implants, revenue growth, and progress toward operational profitability. Any new guidance on future financial performance will be heavily scrutinized.

Beyond the numbers, analysts will be looking for a clear articulation of the company's strategic vision. This includes plans for expanding market access, both within the United States and internationally, and details on the research and development pipeline. The hint in the company's boilerplate about applying the platform to "other brain disorders" is particularly tantalizing for investors seeking significant long-term growth opportunities. Any concrete information on timelines or target indications for this expansion could significantly impact the company's valuation.

"The core technology is impressive, but the investment community needs to see a clear, executable plan for commercial success," stated a financial analyst who covers the medtech sector. "We'll be looking for updates on adoption rates, how they are expanding their sales force, and what the real-world data is telling them about patient outcomes and device longevity. The Leerink conference is their chance to put all the pieces together and show Wall Street that they are not just a science project, but a sustainable and growing business."

As the date of the conference approaches, the presentation represents a confluence of science, medicine, and finance. For NeuroPace, it is a critical opportunity to demonstrate how its mission to transform the lives of people with epilepsy aligns with a strategy to create lasting value for its shareholders. The company's performance in Miami could set the tone for its market narrative for months to come.